Month: May 2025

MIAMI, May 01, 2025 (GLOBE NEWSWIRE) — Today at the F1 Miami Grand Prix circuit, Sir Lewis Hamilton’s global foundation Mission 44 and HP Inc. (NYSE: HPQ) announced a multi-year partnership to fuel access to technology and skills needed to pursue careers in science, technology, engineering, and mathematics. This collaboration unites Mission 44’s drive for greater inclusivity in STEM with HP’s ambition to accelerate digital equity for 150 million people globally by 2030, equipping disconnected adolescents and adults with the critical skills needed to thrive in the future of work. Through targeted initiatives in Miami and then expanding to the UK, the partnership will provide the technology, training, digital skills, and mentorship young people need to unlock opportunities to participate in the digital economy. Mission 44 and HP...

18 presentations across five cancer types include new insights on the potential of checkpoint inhibitors and bispecific antibodies TARRYTOWN, N.Y., May 01, 2025 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced new and updated data from its oncology and hematology portfolio will be shared at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 30 to June 3 in Chicago, IL. Eighteen presentations will share the latest insights from ongoing research of approved and investigational treatment regimens across a range of difficult-to-treat cancers including non-melanoma and melanoma skin cancer, lung cancer, lymphoma and multiple myeloma. “Our broad oncology and hematology programs are uniquely designed to investigate regimens that could provide meaningful impact for...

Marks Key Milestone Toward Becoming a Fully Reporting Public Company ATLANTA, GA, May 01, 2025 (GLOBE NEWSWIRE) — Dinewise, Inc (OTC PINK-DWIS) (referred to as “Dinewise”, “we”, “us”, “our” or the “Company”) A leading national technology conglomerate specializing in automotive, fintech, and entertainment solutions has announced the filing of its Form 10 Registration Statement with the U.S. Securities and Exchange Commission (SEC). Formerly known as Dinewise, the Company will now operate under its new name, Superstar Platforms, Inc., as it transitions into a fully reporting public entity. “This is a pivotal milestone in our company’s journey,” said Michael Farr, CEO of Superstar Platforms, Inc. “From the moment I accepted the role of CEO, I have been laser-focused on providing...

WILMINGTON, Del., May 01, 2025 (GLOBE NEWSWIRE) — Acorn Energy, Inc. (OTCQB: ACFN), a provider of remote monitoring and control IoT solutions for backup power generators, gas pipelines and air compressors, will report Q1 2025 results before the market opens on Thursday, May 8th and host an investor call at 11:00 a.m. ET. Following prepared remarks, Jan Loeb, President & CEO, and Tracy Clifford, CFO & COO of OmniMetrix, will field investor’s questions.Conference Call & ReplayDate/Time: Thursday, May 8th at11:00am ETDial-in Number: 1-844-834-0644 or 1-412-317-5190 (Int’l)Online Replay/Transcript: Audio file/transcript will be posted online hereQuestions can also be submitted via Email to: acfn@catalyst-ir.com   About Acorn (www.acornenergy.com) and OmniMetrixTM (www.omnimetrix.net)Acorn Energy,...

Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discusses key learnings from initial trial phase (“POC 1”) where clinically meaningful pain reduction was demonstrated Outlines Company’s plans to initiate market expansion study (“POC 2”) into additional visceral cancers and earlier stage pancreatic cancer, expected to begin Q2 2025 Access the “What This Means” video here THE WOODLANDS, TX, May 01, 2025 (GLOBE NEWSWIRE) — Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it recently participated in a Virtual Investor “What This Means” segment. For the segment, Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discussed...

Brings Total Assets Raised Across Hybrid and Opportunistic Credit Business to $40 Billion NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) — Apollo (NYSE: APO) today announced it has closed on $8.5 billion in total commitments for the Accord+ strategy, inclusive of $4.8 billion for Accord+ Fund II (“the Fund”) as well as separately managed accounts and related structures. The successful close of the second vintage exceeds internal targets and brings total assets for Apollo’s hybrid credit business to approximately $40 billion. Accord+ II employs an opportunistic strategy focusing on high-conviction investments across the credit spectrum. The Fund is expected to tactically allocate to high quality, top of the capital structure investments across both private corporate credit and asset-backed finance as well as secondary opportunities as...

The industry leader’s Data Security Platform and Managed Data Detection and Response service won awards in four categories for excellence in data security, cloud security, and DSPM MIAMI and SAN FRANCISCO, May 01, 2025 (GLOBE NEWSWIRE) — RSA CONFERENCE 2025 – Varonis Systems, Inc. (Nasdaq: VRNS), the leader in data security, today proudly announced it received four Global Infosec Awards during the RSA Conference 2025. Varonis won the Innovative Service award for its Managed Data Detection and Response. The Varonis Data Security Platform received the Editor’s Choice for Cloud Security, the Market Innovator award for Data-Centric Security, and the Market Innovator award for Data Security Posture Management. The panel of judges recognized Varonis for finding, fixing, and alerting to threats to data across IaaS, SaaS, and hybrid environments...

Research highlights AAV manufacturing optimization via Lexeo’s Sf9-baculovirus process NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) — Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, announced today that new data supporting its AAV manufacturing approach will be presented at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) taking place May 13-17, 2025 in New Orleans, LA. “The data being presented at ASGCT underscore the strength of our industry-leading capabilities in AAV manufacturing with high yield and high quality,” said José Manuel Otero, Chief Technical Officer of Lexeo Therapeutics. “Scientists at Lexeo have optimized a manufacturing platform that can maintain purity and potency while significantly...